• Je něco špatně v tomto záznamu ?

Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-dependent cancers

G. Mudasani, NK. Rampeesa, SR. Anugu, P. Muddasani, S. Gurská, P. Džubák, M. Hajdúch, V. Das, R. Gundla

. 2025 ; 121 (-) : 118116. [pub] 20250220

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009301

Interleukin-2-inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK) are two important members of the Tec family with crucial roles in immune system function. Deregulation in ITK and BTK activity is linked to several hematological malignancies, making them key targets for cancer immunotherapy. In this study, we synthesized a series of azaspirooxindolinone derivatives and evaluated their cytotoxic activity against ITK/BTK-negative and positive cancer cell lines, followed by enzymatic inhibition studies to assess the ITK/BTK kinase selectivity of two hit compounds. Several compounds demonstrated selective cytotoxicity against ITK- or BTK-expressing cells. Compound 3d exhibited high cytotoxicity in ITK-positive Jurkat (IC50 = 3.58 μM) and BTK-positive Ramos (IC50 = 3.06 μM) cells, while compound 3j showed strong cytotoxicity in Ramos (IC50 = 1.38 μM) and Jurkat (IC50 = 4.16 μM) cells. Compounds 3a and 3e were selectively cytotoxic in Jurkat cells (IC50 = 9.36 μM and 10.85 μM, respectively), while compounds 3f and 3g were highly cytotoxic in Ramos cells (IC50 = 1.82 μM and 1.42 μM, respectively). None of the active compounds exhibited cytotoxicity in non-cancer cell lines (IC50 > 50 μM), demonstrating their selectivity for malignant cells. Enzyme inhibition assay showed that 3d is a selective ITK inhibitor (IC50 = 0.91 μM) with no detectable BTK inhibition, aligning with its strong activity in ITK-positive cells. In contrast, compound 3j did not inhibit ITK or BTK enzymatically, suggesting an alternative mechanism of action. These findings highlight 3d as a promising ITK inhibitor and warrant further investigation to elucidate its mechanism of action.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009301
003      
CZ-PrNML
005      
20250429134515.0
007      
ta
008      
250415e20250220enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bmc.2025.118116 $2 doi
035    __
$a (PubMed)40015119
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mudasani, Gopal $u Aragen Lifesciences Pvt. Ltd, Medicinal Chemistry Laboratory Division, Survey No: 125(Part) & 126, IDA Mallapur, Hyderabad 500076, India; Department of Chemistry, School of Science, GITAM University, Hyderabad 502102, Telangana, India
245    10
$a Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-dependent cancers / $c G. Mudasani, NK. Rampeesa, SR. Anugu, P. Muddasani, S. Gurská, P. Džubák, M. Hajdúch, V. Das, R. Gundla
520    9_
$a Interleukin-2-inducible T-cell kinase (ITK) and Bruton's tyrosine kinase (BTK) are two important members of the Tec family with crucial roles in immune system function. Deregulation in ITK and BTK activity is linked to several hematological malignancies, making them key targets for cancer immunotherapy. In this study, we synthesized a series of azaspirooxindolinone derivatives and evaluated their cytotoxic activity against ITK/BTK-negative and positive cancer cell lines, followed by enzymatic inhibition studies to assess the ITK/BTK kinase selectivity of two hit compounds. Several compounds demonstrated selective cytotoxicity against ITK- or BTK-expressing cells. Compound 3d exhibited high cytotoxicity in ITK-positive Jurkat (IC50 = 3.58 μM) and BTK-positive Ramos (IC50 = 3.06 μM) cells, while compound 3j showed strong cytotoxicity in Ramos (IC50 = 1.38 μM) and Jurkat (IC50 = 4.16 μM) cells. Compounds 3a and 3e were selectively cytotoxic in Jurkat cells (IC50 = 9.36 μM and 10.85 μM, respectively), while compounds 3f and 3g were highly cytotoxic in Ramos cells (IC50 = 1.82 μM and 1.42 μM, respectively). None of the active compounds exhibited cytotoxicity in non-cancer cell lines (IC50 > 50 μM), demonstrating their selectivity for malignant cells. Enzyme inhibition assay showed that 3d is a selective ITK inhibitor (IC50 = 0.91 μM) with no detectable BTK inhibition, aligning with its strong activity in ITK-positive cells. In contrast, compound 3j did not inhibit ITK or BTK enzymatically, suggesting an alternative mechanism of action. These findings highlight 3d as a promising ITK inhibitor and warrant further investigation to elucidate its mechanism of action.
650    _2
$a lidé $7 D006801
650    12
$a proteinkinasa BTK $x antagonisté a inhibitory $x metabolismus $7 D000077329
650    12
$a inhibitory proteinkinas $x farmakologie $x chemická syntéza $x chemie $7 D047428
650    12
$a protinádorové látky $x farmakologie $x chemická syntéza $x chemie $7 D000970
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    12
$a screeningové testy protinádorových léčiv $7 D004354
650    12
$a tyrosinkinasy $x antagonisté a inhibitory $x metabolismus $7 D011505
650    _2
$a molekulární struktura $7 D015394
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a oxindoly $x farmakologie $x chemie $x chemická syntéza $7 D000078183
650    _2
$a spirosloučeniny $x chemie $x farmakologie $x chemická syntéza $7 D013141
650    _2
$a simulace molekulového dockingu $7 D062105
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rampeesa, Naveen Kumar $u Aragen Lifesciences Pvt. Ltd, Medicinal Chemistry Laboratory Division, Survey No: 125(Part) & 126, IDA Mallapur, Hyderabad 500076, India; Department of Chemistry, School of Science, GITAM University, Hyderabad 502102, Telangana, India
700    1_
$a Anugu, Sreenivasa Reddy $u Aragen Lifesciences Pvt. Ltd, Medicinal Chemistry Laboratory Division, Survey No: 125(Part) & 126, IDA Mallapur, Hyderabad 500076, India
700    1_
$a Muddasani, Pullareddy $u NATCO Research Center, Sanath Nagar Industrial Area, Sanath Nagar, Hyderabad 500018, Telangana, India
700    1_
$a Gurská, Soňa $u Institute of Molecular and Translational Medicine, Czech Advanced Technologies and Research Institute, Palacký University Olomouc, Křížkovského 511/8, 779 00 Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic
700    1_
$a Džubák, Petr $u Institute of Molecular and Translational Medicine, Czech Advanced Technologies and Research Institute, Palacký University Olomouc, Křížkovského 511/8, 779 00 Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Czech Advanced Technologies and Research Institute, Palacký University Olomouc, Křížkovského 511/8, 779 00 Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic
700    1_
$a Das, Viswanath $u Institute of Molecular and Translational Medicine, Czech Advanced Technologies and Research Institute, Palacký University Olomouc, Křížkovského 511/8, 779 00 Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic. Electronic address: viswanath.das@upol.cz
700    1_
$a Gundla, Rambabu $u Department of Chemistry, School of Science, GITAM University, Hyderabad 502102, Telangana, India. Electronic address: rgundla@gitam.edu
773    0_
$w MED00000769 $t Bioorganic & medicinal chemistry $x 1464-3391 $g Roč. 121 (20250220), s. 118116
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40015119 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134511 $b ABA008
999    __
$a ok $b bmc $g 2310964 $s 1246382
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 121 $c - $d 118116 $e 20250220 $i 1464-3391 $m Bioorganic & medicinal chemistry $n Bioorg Med Chem $x MED00000769
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace